



Supplementary Figure 2. Comparative anti-proliferative effects of trastuzumab, hersintuzumab and their combination in nude mice. SKOV-3 (A) and NCI-N87 (B) xenograft tumor bearing nude mice were treated twice a week with a combination of trastuzumab plus hersintuzumab (5 mg/kg of each), or each mAb alone (10 mg/kg) for 2-3 consecutive weeks. The control group received excipient alone. Tumor sizes were measured three times a week. Data is shown as mean \pm SEM. **** $P < 0.0001$, *** $P < 0.001$, ** $P < 0.01$, ns: non-significant. Tra: trastuzumab. Her: hersintuzumab. Arrows show timing of mAb administration.